Market Cap: $735.74K
CI
Curis, Inc.
CRIS
NASDAQUSD
Market Cap: $735.74K
Curis, Inc. (Ticker: CRIS) advances its clinical research with the recent opening of eleven clinical sites for patient enrollment in its Phase 2 TakeAim CLL study, targeting chronic lymphocytic leukem…
Curis, Inc. (Ticker: CRIS) is in the advanced stages of developing emavusertib, a promising therapeutic candidate that targets significant oncology challenges. The company highlights the ongoing Phase…
Curis Secures $80.8 Million in Private Placement to Advance Emavusertib Development Curis, Inc., a biotechnology company focused on innovative cancer therapies, successfully closes a private placement…
Curis Secures $80.8 Million to Propel Development of Emavusertib Curis, Inc., a biotechnology firm located in Lexington, Massachusetts, is making significant strides in its development efforts by anno…
Curis Secures $80.8 Million Financing to Advance Emavusertib Development Curis, Inc., a biotechnology firm located in Lexington, Massachusetts, announces a significant private placement financing agre…
Curis Advances Treatment Options for Acute Myeloid Leukemia with Promising Clinical Data Curis, Inc., a biotechnology firm focused on innovative cancer therapies, showcases significant advancements in…
Curis Inc. Advances AML Treatment with Promising Emavusertib Data Curis, Inc., a biotechnology firm known for its innovative treatments, presents updated clinical results from its ongoing study of ema…
Curis Advances Neuro-Oncology Research with Promising Emavusertib Data Presentation Curis, Inc., a biotechnology firm focused on innovative cancer therapies, prepares to showcase significant research…
Warner Records Nashville Reimagines Its Future with New Leadership Warner Records Group embarks on a new chapter with the appointment of Cris Lacy as Chair & President of the rebranded Warner Records…
Warner Records Nashville Rebrands Under New Leadership In a significant development for the country music industry, Warner Records Group announces the appointment of Cris Lacy as Chair & President of…
Curis Focuses on Innovative Oncology Solutions Amid Market Developments Curis Inc., a biotechnology company specializing in targeted cancer therapies, continues to advance its mission of developing in…
Curis Inc. Strengthens Talent Pool with New Inducement Stock Options Curis, Inc., a biotechnology enterprise based in Lexington, Massachusetts, actively enhances its workforce by approving inducement…
Curis Amplifies Focus on Emavusertib with Upcoming Conferences Curis, Inc., a biotechnology company headquartered in Lexington, Massachusetts, is poised to enhance its visibility in the oncology secto…
Curis Advances Its Clinical Development of Emavusertib Curis, Inc., a biotechnology firm based in Lexington, Massachusetts, focuses on innovative treatments for cancer and other serious diseases. The…
Curis Prepares for Key Earnings Announcement Amidst Investor Anticipation Curis CRIS is gearing up for its quarterly earnings report scheduled for August 5, 2025, a highly anticipated event for invest…
Strengthening Safety Culture at Michael Baker International In a significant move to bolster workplace safety, Michael Baker International appoints Aaron Gies as Vice President of Health and Safety on…